Skip to content

Alcohol, Inflammation, and Mindfulness Study (AIM)

Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02994043
Enrollment
182
Registered
2016-12-15
Start date
2016-11-09
Completion date
2021-02-17
Last updated
2023-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Use Disorder

Brief summary

The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders (AUD) by implementing an 8-week long intervention and examining neurobiological, immunological, and epigenetic characteristics of AUD.

Detailed description

This study was designed to evaluate the effect of two outpatient, individually-administered, psychosocial interventions (Relapse Prevention vs. Mindfulness-Based Relapse Prevention). Participants are recruited via mass media advertisements, flyers, and local outreach to clinical providers that do not address substance use. We will recruit 226 individuals. Our previous experience with clinical trials, as well as the experience of our research team members with these interventions support the feasibility of recruiting approximately 50 patients per year. This sample size provides adequate statistical power for the research questions undertaken. Participants are screened over the telephone and invited into the laboratory for a baseline assessment. Immediately after the baseline assessment, they are randomized to a therapist and then to a treatment condition. At the end of each year, the distribution of participants across conditions and therapists are evaluated for imbalances. If attrition has resulted in an imbalance across conditions, the randomization procedure will be adjusted to ensure equal numbers of participants in RP and MBRP. Within a week of completing the baseline assessments, participants are seen by their individual therapist for a motivational interviewing, goal-setting session. After the goal-setting session, the eight-session MBRP or RP treatments are administered. To ensure that therapists adhere to treatment manuals, a checklist is provided consisting of the primary content addressed each session (four to seven primary content pieces each session). Further, questionnaires assessing mindfulness practice and facets of mindfulness (e.g., being nonjudgmental, nonreactive) are administered at each assessment. At the most recent RPPR, these questionnaires validated that participants in the MBRP condition were increasing in some facets of mindfulness during treatment (and up to three months after treatment). We estimate that the completion of assessments and procedures across the duration of the trial, excluding therapy sessions, will total about 15 hours of time. To compensate subjects for their time and travel costs, each subject will be paid $300 if they complete all sessions. We will conduct extensive analyses of any attrition encountered in the project to determine bias. However, note that in each of the analyses described herein, we will have the capability of using modern approaches to the handling of missing data including full information maximum likelihood estimation of missing data within Proc Mixed in SAS and within EQS. The distributional properties of all continuously scaled variables will be examined for skewness and kurtosis to determine the need for normalizing transformations or for alternations to our analysis plan (i.e., generalized estimating equations or robust estimation) prior to the primary analyses. To confirm the validity of random assignment, pretest equivalence of the two treatment conditions across demographics, drinking history, smoking, and all other baseline measures will be assessed via t-tests on continuous items and c2 tests of categorical items. We will use the Bonferroni approach to correct for alpha inflation with a familywise alpha of .05. Any variables on which the two groups are unequal at pretest will be covariates in all further analyses. Attrition analyses will be conducted after each follow-up data collection effort to provide assurance that differential attrition by treatment condition has not occurred. Following previously published procedures, a series of ANOVAs of treatment (MBRP versus RP) X retention (retained, not retained) will be conducted on continuous baseline measures. Significant treatment X retention interactions identify measured variables on which differential attrition may have occurred. The logit model analog procedure will be applied to categorical baseline measures to test for differential attrition on categorical variables such as gender and ethnicity. We will conduct these analyses to assure that differential attrition by treatment condition does not account for any of the effects of the treatments.

Interventions

BEHAVIORALMindfulness-Based Relapse Prevention Therapy

An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.

An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.

Sponsors

University of Colorado, Boulder
CollaboratorOTHER
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Have a primary Diagnostic Statistical Manual-V (DSM-V) diagnosis of alcohol use disorder; 2. Must be within 10 days of last drink; 3. Must have been drinking heavily (criteria dependent upon individual?s age, gender, and BMI) for a consistent period of time; 4. Must have a breath alcohol level of 0 at screening; 5. Must have a Clinical Institute Withdrawal Assessment (CIWA) score less than 8 (indicating no need for medical detox); 6. Must have expressed a desire during their initial screen to reduce the number of drinks they regularly consume

Exclusion criteria

1. Currently taking any medications for the treatment of psychiatric disorders, including substance use disorders, mood disorders, and psychosis; 2. Pregnant, as indicated by a pregnancy test which will be administered at baseline; 3. Positive for, sedatives, opiates, cocaine, or amphetamine on drug screen at baseline; 4. Meets criteria for psychotic disorder, bipolar disorder, or a major depressive episode

Design outcomes

Primary

MeasureTime frameDescription
Heavy Drinking Days at Week 32Week 32Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Heavy Drinking Days at BaselineBaselineTimeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Heavy Drinking Days at Week 4Week 4Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Heavy Drinking Days at Week 8Week 8Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)
Heavy Drinking Days at Week 20Week 20Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

Countries

United States

Participant flow

Participants by arm

ArmCount
MBRP
Mindfulness Plus Relapse Prevention Therapy: An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
90
Relapse Prevention
Relapse Prevention Therapy: An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
92
Total182

Baseline characteristics

CharacteristicRelapse PreventionTotalMBRP
Age, Continuous44.2 years
STANDARD_DEVIATION 10.3
44.2 years
STANDARD_DEVIATION 10.1
44.1 years
STANDARD_DEVIATION 10
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants1 Participants0 Participants
Race (NIH/OMB)
More than one race
6 Participants12 Participants6 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
84 Participants168 Participants84 Participants
Sex: Female, Male
Female
48 Participants88 Participants40 Participants
Sex: Female, Male
Male
44 Participants94 Participants50 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 900 / 92
other
Total, other adverse events
0 / 900 / 92
serious
Total, serious adverse events
0 / 900 / 92

Outcome results

Primary

Heavy Drinking Days at Baseline

Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Mindfulness-Based Relapse PreventionHeavy Drinking Days at Baseline12.6 Heavy Drinking DaysStandard Deviation 10.3
Relapse PreventionHeavy Drinking Days at Baseline11.7 Heavy Drinking DaysStandard Deviation 10.5
Primary

Heavy Drinking Days at Week 20

Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

Time frame: Week 20

ArmMeasureValue (MEAN)Dispersion
Mindfulness-Based Relapse PreventionHeavy Drinking Days at Week 206.1 Heavy Drinking DaysStandard Deviation 8
Relapse PreventionHeavy Drinking Days at Week 207.3 Heavy Drinking DaysStandard Deviation 8.8
Primary

Heavy Drinking Days at Week 32

Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

Time frame: Week 32

ArmMeasureValue (MEAN)Dispersion
Mindfulness-Based Relapse PreventionHeavy Drinking Days at Week 324.7 Heavy Drinking DaysStandard Deviation 6.5
Relapse PreventionHeavy Drinking Days at Week 327.7 Heavy Drinking DaysStandard Deviation 8.2
Primary

Heavy Drinking Days at Week 4

Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

Time frame: Week 4

ArmMeasureValue (MEAN)Dispersion
Mindfulness-Based Relapse PreventionHeavy Drinking Days at Week 47.8 Heavy Drinking DaysStandard Deviation 8.2
Relapse PreventionHeavy Drinking Days at Week 47.6 Heavy Drinking DaysStandard Deviation 8.5
Primary

Heavy Drinking Days at Week 8

Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

Time frame: Week 8

ArmMeasureValue (MEAN)Dispersion
Mindfulness-Based Relapse PreventionHeavy Drinking Days at Week 86.5 Heavy Drinking DaysStandard Deviation 7.9
Relapse PreventionHeavy Drinking Days at Week 85.3 Heavy Drinking DaysStandard Deviation 7.6

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026